Dr. Zhu is Professor of Pathology and Pharmacology and Medical Director of Clinical Chemistry/Automated Testing Laboratory,Co-Director of Pathology Core Reference Laboratory, Director of Postdoctoral Clinical Chemistry Training Program, and Chair of Laboratory Utilization Committeeat the Pennsylvania StateUniversity Hershey Medical Center. He is board certified by the American Board of Clinical Chemistry (ABCC) in Clinical Chemistry, Toxicological Chemistry, and Molecular Diagnostics and a Fellow of the AACCAcademy (formerly NACB) since 2007. He served as the President of the North American Chinese Clinical Chemists Association (2012), President of the Commission on Accreditation in Clinical Chemistry (ComACC),Chair of American Association for Clinical Chemistry (AACC) Southeast Section in 2015, Chair of Clinical Translational Science Division (2015-2016), and Secretary of Proteomics & Metabolomics Division (2013-2015) of AACC. Currently, he is the Vice Present of ABCC, Member of AACC Academy Council, and Chair-Elect of Mass Spectrometry & Separation Science Division.Yusheng is on the Editorial Boards of three medical journals and an invited reviewer of seven international medical journals. He has given many presentations at national and international conferences. He has over 115 publications including peer-reviewed papers, editorials, book chapters, and abstracts. He has received 34 awards from AACC, NACB, and other organizations.
Clinical and translational research in clinical chemistry, toxicology, hemoglobinopathy, pharmacogenetics, proteomics, and clinical application of mass spectrometry.
Professor Eva Segelov was appointed as the Professor and Director of Oncology at Monash Health and Monash University in February 2017. She is an Honorary Associate of the NHMRC Clinical Trials Centre, Sydney Medical School. Professor Segelov is an active member of the Australian Gastrointestinal Trials Group (AGITG), as a Board Member and Convenor of the Annual Scientific Meeting. She is Chair of the Gastrointestinal Group of the Clinical Oncological Society of Australia (COSA). In 2016 she was nominated as a European Society of Medical Oncology (ESMO) faculty member for the CUP, Endocrine Tumours, and Others group. She is an Associate Editor of Journal of Global Oncology (ASCO); ESMO 2019 Scientific Sub-Committee member for Neuroendocrine cancer; co-Track Chair of Gastrointestinal Cancer for the 2017 ESMO Asia Annual Scientific Meeting and co-founder of the Commonwealth Neuroendocrine Tumour Society (CommNETS), an international research collaborative. Professor Segelov has led multiple national and international oncology clinical trials, including investigator-initiated studies. Her research interests relate to translational studies of targeted therapies in defined subpopulations to increase benefit and reduce the toxicity of cancer treatments. She has published over 80 articles, expert reviews, and book chapters and is a frequent invited speaker at national and international conferences. She is a panel member of the 2018 L'Oréal-UNESCO For Women in Science Jury. Professor Segelov has a particular interest in professional development using innovative learning techniques and has developed the Seminal Advances Preceptorship in Cancer courses, now being run through Monash University. She was awarded the UNSW Vice Chancellors Award for Teaching Excellence in 2006.
Her research interest mainly focuses on Clinical Trials, Immunotherapy in Colorectal Cancer and Tumor biomarkers.
Dr. Alexander Birbrair obtained a Postdoc from Albert Einstein College of Medicine, Bronx, NY, USA in the Field of Study: Stem cell biology. Currently, he is working as Professor in the Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. He has published 33 publications.
Dr. Alexander Birbrair's research interest includes Stem Cell, Oncology, Therapeutics etc.
In 2013 I obtained PhD in medicine. In 2015 after obtaining habilitation (postdoctoral degree) in medicine, clinical immunology specialty, on the basis of the full scientific record including dissertation entitled: "The presence of Epstein-Barr virus in peripheral blood lymphocytes vs selected immunological parameters and clinical course of chronic lymphocytic leukemia - new aspects of the etio pathogenesis of the disease", I started work as an associate professor at the Chair and Department of Clinical Immunology, Medical University of Lublin, Poland. My research interests focus on the immunology and immunotherapy of human cancers. I am a co-author of 99 academic publications with total Impact Factor (IF) of 121,279 points (h-index=9) as well as numerous chapters in monographs.
Associate Doctor Anil Tombak, M.D. was born on April 25, 1076. He was graduated from Gazi Anatolian High School at 1994, and then graduated from Çukurova University Medical Faculty at 2000. After that he was trained at Mersin University Medical Faculty Internal Medicine Department, and after Internal Medicine specialization, became a fellow of Hematology at the same University. He became a hematologist in 2013 and still working at Mersin University Medical Faculty, Department of Internal Medicine – Hematology, Mersin, Turkey. Associate Doctor Anil Tombak is married and has two children.
His research interest mainly focuses on lymphomas.
Dr. Mohammad S. Hossain obtained his Masters degree in Pharmacy in 1992 from the Department of Pharmacy, Dhaka University, Bangladesh. He conducted research on the structural elucidation of organic compounds isolated from plant parts by different types of chromatographic analysis followed by NMR, MS, IR and UV spectroscopies analysis and anti-microbiological studies of isolated fractions or purified organic compounds. He obtained his PhD in 1999 in experimental viral immunology from the Immunology Laboratory of Professor K. Nomoto MD, PhD, Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. Immediately afterwards, Dr. Hossain moved to the AIDS Research Center, Kumamoto University, Kumamoto, Japan as a post-doctoral fellow. Dr. Hossain has published 19 peer reviewed research articles in highly reputed international journals including Blood, J. Immunology, AIDS, Biology of Blood and Marrow Transplantation etc.
Dr. Hossain's research is to develop new treatment strategies to treat malignant and non-malignant patients with allogeneic HSCT without GvHD and without compromising immune responses to opportunistic infection.
I am employed as a Lead Scientist at Dana Farber Cancer Institute, Boston, USA. I obtained my doctorate in Biochemistry and Molecular Biology from University of Arkansas for Medical Sciences, Little Rock, AR, USA and continued in the same department for postdoctoral training. Subsequently, through a collaboration, I also joined Myeloma Transplantation Research Center at Arkansas Cancer Research Center. In 1999, I was promoted to the position of Instructor at UAMS. From 2001-2006, I worked as Instructor at Harvard Medical School and Harvard (Dana Farber) Cancer Institute, Boston, USA. In 2006, I accepted a position as Director, Surgical Oncology And Developmental Therapeutics Laboratory and Assistant Professor of Surgery at Wayne State University and Karmanos Cancer Institute, Detroit, USA. In 2009, I moved back to Harvard (Dana Farber) Cancer Institute, Boston, USA. I have authored/co-authored more than 60 peer-reviewed scientific publications and serve or have served as Editor, Guest Editor and/or Reviewer for several scientific journals.